FIGO staging of endometrial cancer: 2023
暂无分享,去创建一个
J. Berek | S. Kehoe | X. Matías-Guiu | N. Concin | K. Lindemann | C. Fotopoulou | C. Creutzberg | D. Gaffney | D. Mutch
[1] A. Talhouk,et al. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[2] C. Genestie,et al. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry , 2022, British Journal of Cancer.
[3] A. Mariani,et al. A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer , 2022, International Journal of Gynecological Cancer.
[4] Yu Xu,et al. Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysis. , 2022, Journal of gynecology obstetrics and human reproduction.
[5] E. Ratner,et al. Minimal Uterine Serous Carcinoma and Endometrial Polyp: A Close Clinicopathological Relationship. , 2021, Human pathology.
[6] S. Marnitz,et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma , 2021, Virchows Archiv.
[7] E. Leung,et al. Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancer. , 2021, Brachytherapy.
[8] G. Scambia,et al. Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer , 2021, Journal of gynecologic oncology.
[9] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.
[11] R. Bhargava,et al. Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? - A single-institution study. , 2020, Gynecologic Oncology.
[12] Hui Li,et al. Prognostic value of different metastatic sites for patients with FIGO stage IVB endometrial cancer after surgery: A SEER database analysis , 2020, Journal of surgical oncology.
[13] D. Boll,et al. Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands , 2020, Journal of gynecologic oncology.
[14] C. Aghajanian,et al. Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma. , 2020, Gynecologic oncology.
[15] T. Bosse,et al. Incorporation of molecular characteristics into endometrial cancer management , 2019, Histopathology.
[16] C. Gilks,et al. Interpretation of somatic POLE mutations in endometrial carcinoma , 2019, The Journal of pathology.
[17] C. Gilks,et al. Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.
[18] J. Lang,et al. The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas , 2019, Archives of Gynecology and Obstetrics.
[19] J. McAlpine,et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. , 2019, Gynecologic oncology.
[20] C. Genestie,et al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer , 2019, Histopathology.
[21] A. Mariani,et al. Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells. , 2019, Gynecologic oncology.
[22] A. Berchuck,et al. Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma , 2019, World Journal of Surgical Oncology.
[23] H. Yoshida,et al. Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma , 2018, Journal of gynecologic oncology.
[24] K. Matsuo,et al. Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. , 2017, Gynecologic oncology.
[25] M. Plante,et al. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter? , 2017, Gynecologic oncology.
[26] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[27] R. Sanz-Pamplona,et al. Molecular approaches for classifying endometrial carcinoma. , 2017, Gynecologic oncology.
[28] C. Compton,et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.
[29] A. Talhouk,et al. Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.
[30] M. Leitao,et al. Low-Volume Lymph Node Metastasis Discovered During Sentinel Lymph Node Mapping for Endometrial Carcinoma , 2016, Annals of Surgical Oncology.
[31] J. Ledermann,et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.
[32] N. Sakuragi,et al. Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer , 2015, Journal of gynecologic oncology.
[33] T. Bosse,et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. , 2015, European journal of cancer.
[34] A. Talhouk,et al. A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.
[35] A. Viale,et al. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. , 2015, Journal of the National Cancer Institute.
[36] Yi Kan Wang,et al. Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. , 2015, Journal of the National Cancer Institute.
[37] D. Lambrechts,et al. Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.
[38] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[39] P. Cross,et al. Tumour‐free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer , 2012, BJOG : an international journal of obstetrics and gynaecology.
[40] S. Siesling,et al. Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only , 2011, Obstetrics and gynecology international.
[41] S. Pecorelli. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .
[42] J. Rabban,et al. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis. , 2007, Pathology.
[43] Christopher P Crum,et al. The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.
[44] Jaime Prat,et al. Prognostic parameters of endometrial carcinoma. , 2004, Human pathology.
[45] N. Ramirez,et al. Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer? , 2003, Gynecologic oncology.
[46] V. Abeler,et al. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population , 1991, International Journal of Gynecologic Cancer.
[47] G. Turashvili,et al. Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. , 2019, Gynecologic oncology.
[48] R. Soslow. Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome , 2016, Modern Pathology.
[49] E. Oliva,et al. Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible. , 2013, Gynecologic oncology.
[50] P. Goodfellow,et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. , 2012, Gynecologic oncology.
[51] D. Cohn,et al. Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma. , 2009, Gynecologic oncology.
[52] M. Kelly,et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases , 2005, Modern Pathology.